Yiling Pharmaceutical announced its financial status last night! Wu Yiling’s children are actually the major financial backers behind Jia Nailiang and Luo Yonghao

On the evening of the 28th, Yiling Pharmaceutical announced its financial status.

In 2021, Yiling Pharmaceutical’s revenue was 10.117 billion yuan, a year-on-year increase of 15.19%; net profit was 1.344 billion yuan, a year-on-year increase of 10.27%.

At the same time, the first quarter report of 2022 released by Yiling Pharmaceutical showed that both revenue and net profit fell by more than 20%. During the reporting period, revenue was 2.722 billion yuan, a year-on-year decrease of 25.80%, and net profit was 484 million yuan, a year-on-year decrease of 28.22%.

In early trading on the 29th, Yiling Pharmaceutical's opening fell by 5%. As of 11:30 noon, Yiling Pharmaceutical's market value was 41.484 billion. The company's annual report shows that the company's founder Wu Yiling holds 31.53% of the company's shares, his son Wu Xiangjun holds 20.81% of the shares, and his daughter Wu Rui holds 2.34% of the shares.

Under the leadership of Wu Yiling, the “richest A-share academician”, Yiling Pharmaceutical is a typical family-owned enterprise. His son Wu Xiangjun is the general manager of Yiling Pharmaceutical, his daughter Wu Rui is the secretary of the company's board of directors, and Wu Yiling's nephew Li Chenguang serves as the financial director of a listed company.

The Wu Yiling family’s capital territory spans a wide range of fields, and they are involved in basically every field that ordinary people can think of. According to an incomplete review by NetEase Qingliu Studio, the Wu Yiling family’s investments span multiple industries including fast-moving food, retail, hotels, tourism, medical beauty, film and television, and investment.

Tianyancha shows that there are currently two film and television companies in which Wu Rui has a stake, namely Tianjin Tongle Film and Television Culture Co., Ltd. and Liyi Interactive Entertainment (Tianjin) Film and Television Technology Co., Ltd.

Among them, Tianjin Tongle Film and Television, which was established in March 2016, was originally co-founded by star Jia Nailiang and his agent Guo Hongbo***.

In 2017, Li Xiaolu and Jia Nailiang’s sister Jia Shan’s company was added as a shareholder of the company; from May to July 2018, Tianjin Tongle Film and Television introduced three external investment shareholders, and Wu Rui was one of them. one.

The other two external investment shareholders are private equity funds - Shanghai Ruili Culture M&A Equity Investment Fund Partnership (Limited Partnership) and Shanghai Ruili Culture Development Equity Investment Fund Partnership (Limited Partnership).

According to the equity puncture chart, the shareholders behind Ruili’s merger and acquisition include Yunnan International Trust Co., Ltd., Xinhua Media, and Enlight Media; while the shareholders behind Ruili’s development include SAIC Group, Huali Family, etc.

In February 2022, Li Xiaolu’s company, together with Ruili M&A and Ruili Development, withdrew from Tianjin Tongle Film and Television. Wu Rui is still a shareholder, holding 1.16% of the shares.

Let’s look at the investment landscape of his son Wu Xiangjun and nephew Li Chenguang.

If Wu Yiling himself prefers to invest in start-ups, then the private equity funds in which Wu Xiangjun participates prefer listed companies.

The second largest shareholder of Zhejiang Haining Jiahui Investment Partnership is Wu Xiangjun, who holds 9.1% of the company's shares. The listed companies Haining Jiahui has invested in include Shuhua Sports, Rongke Technology, Zhengyuan Wisdom, etc., and has invested in 16 companies. It is worth mentioning that Haining Jiahui also favors Luo Yonghao and is a shareholder of Smartisan Technology (Chengdu) Co., Ltd.

As Wu Yiling's nephew and the financial manager of Yiling Pharmaceutical, Li Chenguang has his own ideas on investment.

In addition to investing in two animation companies, he holds shares in at least 10 private equity funds or investment institutions, and his interests include automotive travel, artificial intelligence, education and training, medicine, etc.